Filing Details
- Accession Number:
- 0000904454-15-000039
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2015-02-03 12:05:14
- Reporting Period:
- 2014-03-12
- Filing Date:
- 2015-02-03
- Accepted Time:
- 2015-02-03 12:05:14
- Original Submission Date:
- 2014-03-12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1404644 | Aquinox Pharmaceuticals Inc | AQXP | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 200406 | Johnson & Johnson | One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933 | No | No | Yes | No | |
| 924020 | Johnson & Johnson Development Corp Et Al | One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-03-12 | 1,392,094 | $0.00 | 1,392,094 | No | 4 | C | Indirect | Johnson & Johnson Development Corporation |
| Common Stock | Acquisiton | 2014-03-12 | 272,727 | $11.00 | 1,664,821 | No | 4 | P | Indirect | Johnson & Johnson Development Corporation |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | Johnson & Johnson Development Corporation |
| No | 4 | P | Indirect | Johnson & Johnson Development Corporation |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2014-03-12 | 255,681 | $0.00 | 255,681 | $0.00 |
| Common Stock | Series A-2 Preferred Stock | Disposition | 2014-03-12 | 170,454 | $0.00 | 170,454 | $0.00 |
| Common Stock | Series B-1 Preferred Stock | Disposition | 2014-03-12 | 293,884 | $0.00 | 293,884 | $0.00 |
| Common Stock | Series B-2 Preferred Stock | Disposition | 2014-03-12 | 292,532 | $0.00 | 292,532 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2014-03-12 | 379,543 | $0.00 | 379,543 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
- Upon the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock.
Billionaire Hedge Funds
